Net Sales Projections for Full Year to $75 Million--
$75 Million of "NET" sales
This stock should not be under 2 cents
no way!
"For the 2012 first quarter, units sold of our top two products increased dramatically to 770,000, compared with units sold of 78,000 for the same two products in last year's first quarter," said Brad Pyatt, chief executive officer of MusclePharm. "Also during the quarter, we launched new products with a combined total of 300,000 units sold. At the end of the first quarter, we had a sales backlog of $4.3 million, which we shipped in the second quarter of this year. Due to the strong demand we are seeing for our products, combined with the expected near-term launch of 15 new products, we have adjusted our projections for 2012 net sales to $75 million from $40 million."